Pfizer Q3FY26: Income ₹683.24 cr, PAT ₹141.84 cr +17.65% YoY

Regulatory filing: audited FY26 results submitted

Pfizer Limited submitted its audited financial results for the financial year ended March 31, 2026 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Along with the annual results, the company filed a statement of assets and liabilities as on March 31, 2026 and a statement of audited cash flows for the year ended March 31, 2026. The filing also included a declaration that the audit report carried an unmodified opinion. The statutory auditor named in the document is B S R & Co., LLP. The company’s corporate identifiers included CIN L24231MH1950PLC008311 and the NSE symbol PFIZER. The same communication set the context for a board meeting to take the annual and quarterly results on record.

Statutory audit: unmodified opinion from B S R & Co., LLP

In the audit report addressed to the Board of Directors, the statutory auditors said they audited the accompanying annual financial results for the year ended March 31, 2026. The opinion stated that the annual financial results are presented in accordance with the requirements of Regulation 33. It also stated that the results give a true and fair view in conformity with applicable Indian Accounting Standards and generally accepted accounting principles in India. The report noted that the annual financial results include the quarter ended March 31, 2026 as a balancing figure between audited full-year numbers and published unaudited figures up to the third quarter that were subject to limited review. The language in the filing indicates there were no modifications to the opinion.

Board meeting on May 12, 2026: results and dividend on agenda

Pfizer informed BSE that a meeting of the Board of Directors was scheduled to be held on Tuesday, May 12, 2026. The stated agenda included considering, approving and taking on record the financial results for the quarter and year ended March 31, 2026. The board was also to consider a recommendation of dividend, if any, for the financial year ended March 31, 2026. The communication did not specify the dividend amount for FY26.

Q3FY26 snapshot: income rises, PAT also higher

Separately, Pfizer Limited reported performance for the quarter ended December 31, 2025 (Q3FY26). Total income for the quarter was reported at ₹683.24 crore, up 17.65% year-on-year from ₹580.75 crore. Net profit after tax for the quarter was ₹141.84 crore, up 11.18% from ₹127.60 crore. The company also reported net profit before tax for the quarter at ₹191.95 crore versus ₹172.44 crore in the same period last year. Earnings per share for the quarter was stated as ₹31.01 compared with ₹27.89 a year earlier. The company also disclosed total comprehensive income of ₹143.71 crore for the quarter.

Nine-month FY26 performance: income and profit growth

For the nine months ended December 31, 2025, Pfizer reported total income of ₹2,037.65 crore. Net profit after tax for the nine-month period was ₹522.61 crore and earnings per share was ₹114.24. Another disclosure in the provided text compared the nine-month total income with ₹1,817.11 crore in the prior-year period and nine-month net profit with ₹436.66 crore previously. The company stated it operates in a single segment, pharmaceuticals. It also said the results were announced in compliance with Regulation 33 and were made available on stock exchange websites and the company website.

Exceptional items and what drove them

The disclosures referenced exceptional items of ₹58.20 crore for the current quarter and nine months. The exceptional items were linked to two events described in the text. First was a charge of ₹39.58 crore associated with entering an exclusive supply and marketing agreement with Cipla Limited for four brands. Second was an incremental impact of ₹18.62 crore due to an increase in the provision for employee benefits following the consolidation of labour laws into the New Labour Codes effective November 21, 2025, driven primarily by a change in wage definition. The text also noted that exceptional items for the year ended March 31, 2025 included a net gain of ₹172.81 crore from the assignment of a lease and the sale of a building.

FY2025 audited base: revenue, profit, and one-off gains

In its annual report section included in the material, Pfizer reported FY2025 revenue from operations of ₹2,281.35 crore versus ₹2,193.17 crore in FY2024. Profit before tax was ₹1,016.09 crore in FY2025 compared with ₹746.07 crore in FY2024. Profit for the year was ₹767.60 crore versus ₹551.33 crore. The company’s net profit margin was reported at 33.65% in FY2025 compared with 25.14% in FY2024, and it attributed the change mainly to the gain on sale of leasehold rights and buildings at Thane to Zoetis Pharmaceutical Research Private Limited. It also reported return on net worth of 19.65% in FY2025 versus 16.21% in FY2024.

Dividend context: FY2025 payout details disclosed

For FY2025, the Board of Directors at its meeting held on May 19, 2025 recommended a final dividend of ₹35 per equity share and special dividends of ₹100 per share and ₹30 per share. The aggregate dividend for FY2025 was ₹165 per equity share of face value ₹10, and the company disclosed a payout amount of ₹754.84 crore. The annual general meeting referenced in the supplied text approved the dividend payout for FY2025, and another line stated the dividend was paid on July 25, 2025. The May 12, 2026 board agenda indicated a dividend recommendation could be considered for FY2026 as well, but no number was provided in the text.

Corporate actions and audit appointments noted

The material also referenced the appointment of cost and secretarial auditors. It stated that, upon recommendation of the Audit Committee, the Board appointed Kishore Bhatia & Associates as cost auditors for the financial year ending March 31, 2026, with remuneration to be placed before shareholders for ratification at the ensuing annual general meeting. It also stated Parikh & Associates, Company Secretaries, were appointed as secretarial auditors for five consecutive financial years from FY2025-26 to FY2029-30, subject to member approval.

Key numbers table: Q3FY26 and nine-month performance

Stock snapshot and identifiers mentioned in the text

As per the market snapshot included in the provided material (timestamped “As on 31 Mar 2026 | 15:20”), Pfizer was shown with market cap of ₹21,591.79 crore, P/E of 28.35 and EPS of 166.47. It also listed book value of 841.20, dividend yield of 3.5% and face value of ₹10. The identifiers included BSE code 500680 and ISIN INE182A01018. These figures were presented as a snapshot and not as part of the audited FY26 financial statements.

Why this matters for investors tracking Pfizer

The audited filing and unmodified opinion provide the compliance framework under which Pfizer reports its annual numbers. The May 12, 2026 board meeting agenda is relevant because it covers both approval of results for the quarter and year ended March 31, 2026 and a potential dividend recommendation. The quarterly and nine-month numbers cited in the material show how profitability and income moved during FY26 up to December 2025, including the effect of exceptional items. The FY2025 annual report numbers in the text also show how one-off gains can influence margins and return metrics, which helps in comparing year-to-year profitability.

Conclusion

Pfizer’s filings referenced audited FY26 results with an unmodified audit opinion from B S R & Co., LLP, and a board meeting on May 12, 2026 to take the results on record and consider a dividend recommendation. Separately disclosed Q3FY26 and nine-month figures showed total income of ₹683.24 crore for Q3FY26 and ₹2,037.65 crore for the nine months ended December 2025, alongside reported exceptional items of ₹58.20 crore. The next confirmed step in the supplied text is the board’s consideration and approval process for the quarter and year ended March 31, 2026.